solnerstotug
Generic: Solnerstotug·Code: SNS-101
solnerstotug: developed by 1 company · 1 clinical trial tracked.
solnerstotug evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect solnerstotug to SNSE; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could solnerstotug → SNSE affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 1 study sponsors
Development Pipeline (1)
| Company | Phase |
|---|---|
| Sensei Biotherapeutics, Inc. (SNSE) | Phase 2 |
Clinical Trials (1)
A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SNS-101 (Anti VISTA) as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Primary endpoint: Adverse Events - Part A & B
Interventionalopen98 targetStarted 2023-05Completion 2027-0610 sites · United StatesSensei Biotherapeutics, Inc.
Frequently asked questions
Who is developing solnerstotug?
solnerstotug is being developed by Sensei Biotherapeutics, Inc..
How many clinical trials involve solnerstotug?
BioSniper tracks 1 clinical trial involving solnerstotug.